UNSPSC 51281715: Ampicillin benzathine

This classification denotes a penicillin antibiotic with the molecular structure C16H20N2.2C16H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1TD7AM884 chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more commonly known as ampicillin benzathine, which bears US NIH Compound Identifier 94447.

UNSPSC 51281715 Ampicillin benzathine is a Commodity code that nominally names a specific antibiotic product, but recent state and local procurement activity under this code shows a significant mismatch: the actual solicitations posted involve naloxone, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs. None of the recent opportunities explicitly reference ampicillin benzathine or align with the code's stated scope. The issuing bodies are a mix of county health departments, municipal fire departments, state health agencies, and cooperative purchasing alliances, suggesting that the code may be applied inconsistently across jurisdictions or that the code designation reflects a broader pharmaceutical category rather than the specific named product.

Geographic activity spans Florida (Seminole County), Texas (HHS Commission), Minnesota and Oregon (through MMCAP cooperative purchasing), and Tampa, Florida. Representative recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (posted June 30, 2026); the City of Tampa's IFB 26P00145 for medical and first aid supplies for the Fire Department with a $700,000 estimated contract value and sealed-bid submission by March 13, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, distributed through three authorized wholesalers and effective July 1, 2026. The Texas HHS Commission's RFI HHS0017013 for a Direct-to-Manufacturer Prescriptions program, with an April 3, 2026 response deadline, represents exploratory market intelligence rather than a formal competitive solicitation. The code shows limited concrete activity directly aligned with ampicillin benzathine procurement.